❮ Back to Researchers

Jiwon Oh

MD, PhD

Scientist

Email: Jiwon.Oh@unityhealth.to
Tel: 416-864-6060 ext. 2282

Research Programs

Biography

Research Interests

Multiple sclerosis (MS), MRI biomarkers with clinical utility in prognostication and disease monitoring, cohort studies

Research Activities

Jiwon Oh is a staff neurologist, scientist, and Medical Director of the Barlo Multiple Sclerosis (MS) Program at St. Michael’s Hospital, University of Toronto. Dr. Oh’s research focuses on developing advanced MRI techniques in the spinal cord and brain for use in clinical settings. She leads the MRI research program at St. Michael’s Hospital, and is the principal investigator on numerous local and multi-center collaborative studies, including the Canadian Prospective Cohort Study to Understand Progression in MS (CanProCo), which is a national prospective cohort study designed to better understand progression in MS.

Recent Publications

  1. Sawicka, KM, Feldman, BM, Beyene, J, Finlayson, M, Guenette, M, Liu, K et al.. Age of multiple sclerosis symptom onset affects mental and physical health-related quality of life in opposite directions. Mult Scler Relat Disord. 2025;101 :106561. doi: 10.1016/j.msard.2025.106561. PubMed PMID:40540923 .
  2. Ghassabian, A, Dickerson, AS, Wang, Y, Braun, JM, Bennett, DH, Croen, LA et al.. Prenatal Air Pollution Exposure and Autism Spectrum Disorder in the ECHO Consortium. Environ Health Perspect. 2025; :. doi: 10.1289/EHP16675. PubMed PMID:40498638 .
  3. Freedman, DE, Sundaram, ANE, Oh, J, Feinstein, A. How Does Time-of-Testing Influence Cognitive Performance in Multiple Sclerosis?. Can J Neurol Sci. 2025; :1-3. doi: 10.1017/cjn.2025.10125. PubMed PMID:40386948 .
  4. Freedman, DE, Oh, J, Einstein, G, Feinstein, A. Aging and the neuropsychiatry of multiple sclerosis: a cross-sectional study. J Neurol. 2025;272 (5):375. doi: 10.1007/s00415-025-13116-x. PubMed PMID:40319422 .
  5. Sureshkumar, A, Luong, D, Munce, S, Bayley, M, Kastner, M, Scandiffio, J et al.. Implementation considerations of key knowledge users for building online mindfulness-based interventions for people with multiple sclerosis. Disabil Rehabil. 2025; :1-13. doi: 10.1080/09638288.2025.2492312. PubMed PMID:40237065 .
  6. Müller, J, Sharmin, S, Lorscheider, J, Ozakbas, S, Karabudak, R, Horakova, D et al.. Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis. JAMA Neurol. 2025;82 (6):614-625. doi: 10.1001/jamaneurol.2025.0495. PubMed PMID:40227706 PubMed Central PMC11997854.
  7. Oh, J, Arnold, DL, Cree, BAC, Ionete, C, Kim, HJ, Sormani, MP et al.. Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis. N Engl J Med. 2025;392 (19):1893-1904. doi: 10.1056/NEJMoa2415985. PubMed PMID:40202623 .
  8. Sureshkumar, A, Scandiffio, J, Luong, D, Munce, S, Lai, N, Feng, G et al.. Implementing a new clinical service - what's your elevator pitch?. BMC Health Serv Res. 2025;25 (1):462. doi: 10.1186/s12913-025-12633-9. PubMed PMID:40156017 PubMed Central PMC11951556.
  9. Zeydan, B, Neyal, N, Nathoo, N, Rangachari, M, Atkinson, EJ, Son, J et al.. Effects of androgen modifying therapies on disease activity in older men with multiple sclerosis. J Neuroimmunol. 2025;403 :578589. doi: 10.1016/j.jneuroim.2025.578589. PubMed PMID:40139128 PubMed Central PMC12048229.
  10. Freedman, DE, Oh, J, Meza, C, Feinstein, A. Seizure history and cognitive dysfunction in people with multiple sclerosis. Mult Scler. 2025;31 (6):668-676. doi: 10.1177/13524585251326841. PubMed PMID:40099830 PubMed Central PMC12092947.
Search PubMed

Affiliations & Other Activities

  • Staff Neurologist, Division of Neurology, Department of Medicine, St. Michael’s Hospital
  • Associate Professor, Department of Medicine, University of Toronto
  • Adjunct Faculty, Department of Neurology, Johns Hopkins University